Previous Close | 0.0300 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.0300 - 0.0300 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Unveiling key financial outcomes and strategic milestones, Capricor Therapeutics sets a robust path for 2024.
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meetin